Slone Partners Places Kurt Gish as Chief Scientific Officer at BioLoomics

Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, has announced the placement of Kurt Gish Ph.D., as Chief Scientific Officer at BioLoomics, a biotechnology company that targets peptide-antibody chimeras to specific compartments inside of diseased cells. Dr Gish will focus on building the company’s pipeline of lysosomal targeting ADCs in oncology to overcome the limitations of poor tumor uptake, which hinders safety and efficacy across the ADC market.

Prior to BioLoomics, Dr. Gish served as Chief Scientific Officer and Founder of Trilo Therapeutics where he pioneered a novel DNA encoded library approach to build D-peptide conjugates to rival traditional ADC modalities. Prior to Trilo, Dr. Gish was an early pioneer in ADCs at AbbVie, investigating novel linkers and payloads, exploring the nature of antigen-independent toxicity and driving two ADC programs into human clinical trials. He serves on the scientific advisory board of the Myeloma Investment Fund of the Multiple Myeloma Research Foundation.

“Kurt Gish is a tremendously talented and highly respected scientist and business leader with a history of driving the development of innovative therapies and treatments,” said Leslie Loveless, CEO and Managing Partner at Slone Partners. “As BioLoomics continues seeking new solutions to unlock the many mysteries of cancer, Dr. Gish will play an important role as part of the company’s leadership team.”

“Kurt is an impressive and accomplished scientist who sits at the intersection of ADCs, peptides, and target discovery/validation. He has a deep understanding of how improper spatial targeting of ADCs has limited the field,” said Doug Chapnick, Founder and CEO of BioLoomics. “With his deep experience in the ADC space, I am confident that Kurt will be invaluable to advancing BioLoomics’s technology to build safer and more efficacious ADCs for both strategic partners and internal programs.”

“BioLoomics is developing incredible technology to deliver more therapeutic drugs directly into cancer cells while minimizing systemic toxicity,” remarked Dr. Gish. “I’m thrilled to join such an innovative team and look forward to getting the best possible treatments to patients who so desperately need them.”

Dr. Gish earned his Ph.D. in Biology from Stanford University and studied molecular immunology during his postdoctoral fellowship at the DNAX Research Institute.

Founded in 2000, Slone Partners is a premier executive search firm that delivers visionary leaders who build amazing life sciences and healthcare organizations. With a nationwide presence in the most active industry hubs, we specialize in discovering and placing world-class Board, C-Suite leadership, and upper management talent with experience, conviction, and cultural competence in emerging and well-established companies. Our portfolio of executive search and advisory services includes customized cultural solutions through strategic planning, education, training, and coaching. Slone Partners proudly holds the designation as a Certified LGBT Business Enterprise™ by the National Gay & Lesbian Chamber of Commerce (NGLCC) and has earned recognition as a Top Executive Search Firm and a Top 20 Diversity and Inclusion Services firm by Manage HR. To learn more about Slone Partners’ value proposition and processes, visit or call 888.784.3422.

Headquartered in Colorado, BioLoomics is a preclinical stage biotechnology company pioneering directed evolution of antibody-peptide chimeras with programmable cell entry and lysosome targeting. Lysosome targeted antibody-peptide chimeras have broad utility to elicit increased payload delivery mechanisms in the ADC therapeutic space, as well as target degradation in the biologics therapeutic space. The company has raised a total of $10.1 million from top investors including Innovations Endeavors, Horizons Ventures, TechU Ventures, Boom Capital Ventures, BoxOne Ventures, GC&H, and Viswa Colluru.

Share This Article